NCT03697564View on ClinicalTrials.gov

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

April 12, 2023

Study Completion Date

July 13, 2023

Conditions
Pancreatic Cancer Stage IV
Interventions
DRUG

Gemcitabine

1000 mg/m2 IV on days 1, 8, and 15 Q4W

DRUG

Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]

480mg IV on Day 1 Q4W

DRUG

Cabiralizumab

4mg/kg IV on day 1 and 15 Q4W

Trial Locations (1)

92093

UCSD Moores Cancer Center, La Jolla

All Listed Sponsors
collaborator

Stand Up To Cancer

OTHER

collaborator

Lustgarten Foundation

OTHER

lead

Hitendra Patel

OTHER

NCT03697564 - Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer | Biotech Hunter | Biotech Hunter